Link: https://links.sgx.com/1.0.0/corporate-announcements/JZMG46GN40CW2ZML/bfdcf5347d5daa5c805f560256d81e5fc7da03941ae569dcce4fea167f1a2506

Summary:

• Revenue: S$15.7 million (down 6% from S$16.6m in FY2024)

• Net Loss: S$26.16 million (improved vs. S$37.45m loss in FY2024)

  • Includes a main loss from continuing operations; discontinued operations loss negligible.

• Gross Profit & Margin: Not separately detailed, but cost control and higher other income/gains improved the operating result.

• Key Expense Changes:

  • Medical consultancy fees fell 24% (to S$1.59m, mainly lower for aesthetics).

  • Repair/maintenance rose 36% (to S$6.05m, due to medical equipment upkeep).

  • Finance costs dropped sharply (by 73%) due to lower loan costs and settlement.

  • Depreciation: S$11.90m; Impairment on PPE: S$2.47m

• Cash and Equivalents: S$2.84 million (down from S$3.16m)

• Total Assets: S$124.6 million (down from S$138.8m)

• Net Asset Value per Share: 5.24 cents (down from 7.80c)

• Borrowings: S$3.66 million (down from S$6.24m), excludes shareholder and non-related party loans, which rose.

• Equity: S$55.64 million (down from S$81.7m)

• No Dividend

• Notable Developments:

  • Signed agreements with Singapore/China insurance and real estate agencies for referral and screening expansion.

  • Business development initiatives to enhance patient intake, clinical research.

  • Key loans were extended; shareholder and related party support in place to address going concern risk.

Outlook: While top-line revenue slipped and losses remain, SAM Holdings narrowed losses with better finance management, external support, and cost control. Marketing and partnership initiatives, plus capital support, are expected to stabilize and grow business in the next year. No dividend is declared as the company focuses on recovery and operational improvement.